Ranitidine prescription capsules recall - Avkare Pharmaceuticals

21 de Noviembre del 2019

On October 25, 2019, Avkare Pharmaceuticals issued a voluntary recall of prescription ranitidine capsules manufactured by Dr. Reddy’s and distributed by AvKare Pharmaceuticals due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will send a letter to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

Product Description


Ranitidine 150mg Capsules


Ranitidine 300mg Capsules


Additional information is available on the FDA’s website:


Última actualización: 08 de Diciembre del 2023